PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-3.71%
Revenue decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate if market share loss is temporary.
-4.03%
Cost reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive advantage potential.
-2.36%
Gross profit decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.
1.40%
Margin change of 1.40% versus flat Medical - Pharmaceuticals margins. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.19%
Other expenses change of 1.19% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify efficiency.
2.04%
Operating expenses growth below 50% of Medical - Pharmaceuticals median of 4.68%. Joel Greenblatt would investigate efficiency.
-3.08%
Total costs reduction while Medical - Pharmaceuticals median is 5.02%. Seth Klarman would investigate advantages.
53.33%
Interest expense change of 53.33% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify control.
0.57%
D&A growth near Medical - Pharmaceuticals median of 0.62%. Charlie Munger would verify industry norms.
-17.14%
EBITDA decline while Medical - Pharmaceuticals median is -1.27%. Seth Klarman would investigate causes.
-13.95%
EBITDA margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-16.80%
Operating income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-13.59%
Operating margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-21.58%
Other expenses reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
-17.33%
Pre-tax income decline while Medical - Pharmaceuticals median is -1.28%. Seth Klarman would investigate causes.
-14.15%
Pre-tax margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-16.44%
Tax expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
-17.89%
Net income decline while Medical - Pharmaceuticals median is -1.30%. Seth Klarman would investigate causes.
-14.73%
Net margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-17.88%
EPS decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-17.88%
Diluted EPS decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-0.00%
Share count reduction while Medical - Pharmaceuticals median is 0.13%. Seth Klarman would investigate strategy.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.03%. Seth Klarman would investigate strategy.